[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-377773-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-377773-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","novel-therapeutic-strategies-for-essential-thrombocythemiapolycythemia-vera","Novel therapeutic strategies for essential thrombocythemia/polycythemia vera","","Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem-cell disorders including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). MPNs behave as inflammatory cancers: malignant clones generate cytokines that sustain a self-perpetuating cycle, driving symptoms such as fatigue, weakness, and pruritus. Inflammation also worsens thrombosis and bleeding, contributing to morbidity and mortality. This review highlights evolving ET/PV approaches and new therapies under clinical development, including active treatment interests in low-risk PV/ET.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/novel-therapeutic-strategies-for-essential-thrombocythemiapolycythemia-vera/377773/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/novel-therapeutic-strategies-for-essential-thrombocythemiapolycythemia-vera/377773.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are the main inflammatory drivers in MPNs such as ET and PV?","Question",{"text":63,"@type":64},"MPNs are inflammatory clonal disorders where malignant clones generate cytokines. These cytokines sustain a self-perpetuating inflammatory drive that contributes to both symptoms and complications.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is thrombosis risk used to guide current ET and PV treatment?",{"text":68,"@type":64},"Patients are classified into low-risk and high-risk categories based on thrombosis risk. Risk categories are defined using criteria adopted from expert studies and international scoring systems.",{"name":70,"@type":61,"acceptedAnswer":71},"What treatment goals have changed in ET/PV management over time?",{"text":72,"@type":64},"The earlier main objective was preventing thrombosis to improve survival. More recent therapies also aim to modify disease course and provide symptom relief, with growing interest in treating selected low-risk patients more actively.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},377773,1790342408,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","| BLOOD RESEARCH | VOLUME 58 ㆍ | NUMBER S1\u003Cbr>April 2023 | REVIEW ARTICLE |\n| --- | --- | --- | --- |\n\nNovel therapeutic strategies for essential thrombocythemia/polycythemia vera  \nSeug Yun Yoon, Jong-Ho Won  \nDivision of Hematology & Medical Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea  \n\n| p-ISSN 2287-979X / e-ISSN 2288-0011 [https://doi.org/10.5045/br.2023.2023013](https://doi.org/10.5045/br.2023.2023013)\u003Cbr>Blood Res 2023;58:S83-S89.\u003Cbr>Received on January 16, 2023 Revised on April 17, 2023\u003Cbr>Accepted on April 17, 2023\u003Cbr>*This study was supported by the Soonchunhyang University Research Fund.\u003Cbr>Correspondence to\u003Cbr>Jong-Ho Won, M.D., Ph.D.\u003Cbr>Division of Hematology & Medical Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, 59 Daesagwan-ro, Yongsan-gu, Seoul 04401, Korea [E-mail: jhwon@schmc.ac.kr](E-mail: jhwon@schmc.ac.kr)[ ](E-mail: jhwon@schmc.ac.kr)Ⓒ 2023 Korean Society of Hematology | Abstract\u003Cbr>Myeloproliferative neoplasms (MPNs) are clonal disorders of hematopoietic stem cells; these include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). MPNs are inflammatory cancers, wherein the malignant clone generates cytokines that sustain the inflammatory drive in a self-perpetuating vicious cycle. The course of MPNs follows a biological continuum, that is, from early cancer stages (ET/PV) to advanced myelofibrosis as well as impending leukemic transformation. MPN-related symptoms, e.g., fatigue, general weakness, and itching, are caused by inflammatory cytokines. Thrombosis and bleeding are also exacerbated by inflammatory cytokines inpatients with MPN. Until recently, the primary objective of ET and PV therapy was to increase survival rates by preventing thrombosis. However, several medications have recently demonstrated the ability to modify the course of the disease; symptom relief is expected for most patients. In addition, there is increasing interest in the active treatment of patients at low risk with PV and ET. This review focuses on the ET/PV treatment strategies as well as novel treatment options for clinical development.\u003Cbr>Key Words Polycythemia vera, Essential thrombocythemia, Novel therapeutics |\n| --- | --- |\n\nINTRODUCTION  \nPhiladelphia chromosome-negative myeloproliferative neoplasms (MPNs) are clonal disorders of hematopoietic stem cells; these include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). PV and ET are the most common subtypes of MPNs. In the United States, the incidences of PV and ET are comparable at 1.0– 2.0/100,000 person-yr. However, PMF remains uncommon, having an incidence of 0.3/100,000 person-yr [1]. The prevalence of PV and ET is estimated to be 44–57 and 38– 57/100,000 people, respectively, in the United States (US)  \n[2] . Caucasians showed a higher incidence of MPNs; East Asians and Africans showed a higher incidence of ET; Caucasians and Hispanics showed a higher incidence of PV [3] .  \nMPNs are inflammatory cancers, wherein the malignant clone generates cytokines that sustain the inflammatory drive in a self-perpetuating vicious cycle. MPNs are linked to orga-  \nnomegaly, cytopenia, and a variety of constitutional complaints, which may significantly impair an individual’s quality of life. The course of MPNs follows a biological continuum, that is, from early cancer stages (ET/PV) to advanced myelofibrosis as well as impending leukemic transformation. Therefore, monitoring the transformation of ET/PV to MF/AML is paramount. However, there are no approved therapeutic regimens to prevent this progression. Additionally, thrombosis, which occurs in 20–30% of the patients, is a major contributor of ET-and PV-associated morbidity and mortality [4] . Therefore, classifying risk categories and attaining suitable thrombosis prevention for each category are the basis of current ET and PV treatments.  \nCURRENT TREATMENT ST","cbCaiqenRmd80HJx","https://ap.wps.com/l/cbCaiqenRmd80HJx","pdf",378426,"English","# Introduction\n## Current treatment strategies for patients with PV/ET\n## Risk stratification and thrombosis prevention","[{\"question\":\"What are the main inflammatory drivers in MPNs such as ET and PV?\",\"answer\":\"MPNs are inflammatory clonal disorders where malignant clones generate cytokines. These cytokines sustain a self-perpetuating inflammatory drive that contributes to both symptoms and complications.\"},{\"question\":\"How is thrombosis risk used to guide current ET and PV treatment?\",\"answer\":\"Patients are classified into low-risk and high-risk categories based on thrombosis risk. Risk categories are defined using criteria adopted from expert studies and international scoring systems.\"},{\"question\":\"What treatment goals have changed in ET/PV management over time?\",\"answer\":\"The earlier main objective was preventing thrombosis to improve survival. More recent therapies also aim to modify disease course and provide symptom relief, with growing interest in treating selected low-risk patients more actively.\"}]","Novel therapeutic strategies for essential thrombocythemia/polycythemia vera | PDF",1790227074,18]